Abstract A090: Vepugratinib (LY3866288), a potent highly isoform-selective FGFR3 inhibitor, enhances the activity of enfortumab vedotin (EV) in FGFR3-altered metastatic urothelial cancer (mUC) models
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Eva Goetz, Viviana Volta, Haniyeh Eyvani, Robert John . Evans, Bojana Jovanovic, Wei-Jen Chung, Marie Mutryn, Supreet Agarwal, Franny Hough, Audrey Au, Wei Zheng, Timothy Bailey, Marguerita O'Mahony, Abhinav Achreja, Sarah M. Bogner, Joseph Puccini, Cindy Lee, Jason Manroe, Brent D. Butts, Yu-Huan Shih, Farideh Ordikhani, Rowena Almonte-Baldonado, Chun Ping Yu, Wei Guo Xu, Andrew Capen, Veena Coothan Kandaswamy, Vanessa Rodrik-Outmezguine, Karsten Boehnke, Loredana Puca
Institutions: Eli Lilly (United States), Lilly (China)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415444382
Cites:
Cited by:
Related to: